Pneumococcal vaccines for preventing otitis media

Straetemans, Masja; Sanders, E. A. M.; Veenhoven, RH; Schilder, Anne G. M.; Damoiseaux, Roger; Zielhuis, G.A.

doi:10.1002/14651858.cd001480

Cited by 26 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PCV-7 effectiveness against IPD and pneumonia of unspecified aetiology was modelled according to the data from a meta-analysis on protective efficacy against vaccine-type IPD and X-ray confirmed pneumonia [9], after adjusting for the percentage of serogroups covered by the vaccine with the hypothesis of complete cross-reactivity between serotypes [5]. The prevention rate of pneumococcal conjugate vaccine against AOM was derived from another meta-analysis [10]. Vaccine effectiveness parameters are shown in Table 1.…”

Section: Vaccine Parameters and Proceduresmentioning

confidence: 99%

“…The vaccine also has a weaker but proven efficacy on pneumonia and otitis media, where the number of cases averted is quite high, even though it only provides a protection rate of 20% and 7%, respectively [9,10].…”

Section: Effect On the Burden Of Diseasementioning

confidence: 99%

“…Pneumococcal disease in children is one of the most relevant infectious diseases in industrialised countries for three major reasons: (1) Streptococcus pneumoniae causes a large spectrum of diseases, some of them extremely common, such as pneumonia and acute otitis moedia [1][2][3][4]; (2) after the decline of the Haemophilus influence b (Hib) following the diffusion of the anti-Hib vaccine, it is the most common aetiological agent in infant meningitis [5][6][7][8]; (3) a safe, effective heptavalent conjugate vaccine is now available [9][10][11].…”

Section: Introductionmentioning

confidence: 99%

“…In particular, the vaccine is highly effective against meningitis and other invasive diseases [9], which are very severe but extremely rare events [5], but less effective against pneumonia and otitis, which are less severe but occur with extreme frequency [10]. The vaccine is very expensive compared to other routinely administered vaccines.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy

Rossi¹,

Merito

Borgia³

2009

Health Policy

View full text Add to dashboard Cite

Section: Vaccine Parameters and Proceduresmentioning

confidence: 99%

Section: Effect On the Burden Of Diseasementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy

Rossi¹,

Merito

Borgia³

2009

Health Policy

View full text Add to dashboard Cite

“…To date, trials of pneumococcal vaccines have mainly focused on the prevention of AOM. Pooled analyses of the results of these trials indicate that the 8-and 14-valent pneumococcal polysaccharide vaccines (PPV) might prevent about 10% of AOM episodes and that the 7-and 9-valent pneumococcal conjugate vaccines (PCV) may prevent about 8% of AOM episodes in young children who receive these vaccinations before the age of 6 months [16]. Studies investigating the effect of pneumococcal vaccination on OME, however, are scarce [10,15,17].…”

Section: Introductionmentioning

confidence: 99%

Effect of pneumococcal vaccination on otitis media with effusion in children older than 1 year

Rovers

Veenhoven

et al. 2006

Eur J Pediatr

View full text Add to dashboard Cite

Pneumococcal vaccines may be effective in preventing or decreasing the burden of disease related to otitis media. In study reported here, we investigated the effectiveness of pneumococcal vaccination on otitis media with effusion (OME) in children (n = 383 children aged 1-7 years) with a history of recurrent otitis media within the framework of a randomized double blind placebo controlled trial. Children were randomized to be immunized with either a 7-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine, or by hepatitis A or B vaccines. The proportion of children diagnosed with OME at the scheduled follow-up visits--7, 14, 20 and 26 months after randomization--was then calculated. OME was diagnosed according to an algorithm combining tympanometry and otoscopy. The percentage of children diagnosed with OME was similar in the pneumococcal vaccination group and control group at both baseline and the follow-up visits at 7, 14, 20 and 26 months--52.9 versus 52.7, 44.9 versus 44.2, 34.9 versus 31.5, 40.8 versus 32.2 and 31.4 versus 26.1, respectively (corresponding to p-values of 0.96, 0.89, 0.51, 0.13 and 0.36, respectively). We conclude that the combined pneumococcal conjugate and the polysaccharide vaccination have no beneficial effect on OME in children aged 1 year or older with a history of recurrent otitis media. Therefore, these vaccinations are not indicated in the prevention of OME in these children.

show abstract